RESUMEN
Psoriasis is a chronic inflammatory skin disease characterized by alterations in cytokines produced by both Th1 and Th17 pathways. The aim of this study was to evaluate serum levels of pivotal cytokines and correlate them with clinical parameters. Serum samples from 53 psoriasis patients and 35 healthy volunteers, matched by the proportion of sex and age ratios, were collected for ELISA cytokine detection. Psoriasis Area and Severity Index (PASI) was assessed at the time of sampling in psoriasis patients. Our findings demonstrate that IL-17A, IL-22, and IL-6 serum concentrations were significantly higher in psoriasis patients than in the control group. No statistical correlation could be found between cytokines concentrations, PASI score, and age in this study. Although our results do not show any correlation between serum levels of IL-17A, IL-22, and IL-6 and disease activity, the present study confirms that they were increased in Brazilian psoriasis patients in comparison to healthy volunteers.
Asunto(s)
Interleucina-17/sangre , Interleucina-6/sangre , Interleucinas/sangre , Psoriasis/sangre , Adulto , Brasil , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Persona de Mediana Edad , Interleucina-22RESUMEN
OBJECTIVE AND DESIGN: To evaluate the effects of simvastatin in peripheral blood mononuclear cell (PBMC) cytokines profiles and correlate with the disease state of rheumatoid arthritis (RA) patients. METHODS: The PBMC from 22 RA patients were purified and stimulated or not stimulated with phorbol myristate acetate/ionomycin and were treated with simvastatin in different doses. Cytokine levels were quantified by ELISA and patients were assessed for clinical and laboratory variables. This assessment included disease activity measures [Clinical Disease Activity Index (CDAI), Disease Activity Score for 28 joints (DAS28)] and a Health Assessment Questionnaire. RESULTS: The IL-17A, IL-6, IL-22 and IFN-γ were significantly reduced in a dose response after simvastatin treatment (50 µM, p = 0.0005; p < 0.0001; p < 0.02; p = 0.0005, respectively). The IL-17A and IL-6 cytokines were also significantly reduced in lower concentrations of simvastatin (10 µM) compared to controls (p = 0.018; p = 0.04) and compared to the standard drug (p = 0.007; p = 0.0001). The results also showed that only RA patients with severe disease (DAS28 >5.1 and CDAI >22) had poor response to simvastatin in reducing cytokines levels, mainly for IL-17A and IL-22 cytokines (p = 0.03; p = 0.039, respectively). CONCLUSION: The RA patients in clinical remission, mild or moderate had lower levels of all cytokines analyzed after simvastatin treatment, showing that these patients have better response to treatment. Our findings suggest that the simvastatin therapy modulates different cytokines in a dose dependent manner and its effect is associated with stratification of patients according to disease activity.
Asunto(s)
Artritis Reumatoide/inmunología , Citocinas/antagonistas & inhibidores , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Simvastatina/farmacología , Adulto , Anciano , Citocinas/inmunología , Relación Dosis-Respuesta a Droga , Relación Dosis-Respuesta Inmunológica , Femenino , Humanos , Leucocitos Mononucleares/inmunología , Masculino , Persona de Mediana EdadRESUMEN
AIM: to investigate the effects of the whole body vibration (WBV) and inspiratory muscle training (IMT) on the inflammatory profile and in muscle mass and strength in pre-frail older women. METHODS: this study was a randomized double-blind trial. Forty two older women aged 60-80 years were randomly allocated to IMT + WBV (G1), IMTsham + WBV (G2) or Sham groups (G3). During 12 weeks G1 received both trainings, whereas G2 received WBV alone and G3 received IMT with a low fixed load and were positioned at the vibratory platform without therapeutic effect. Participants were evaluated before and after the intervention for the following outcomes: Brain-derived neurotrophic factor (BDNF) and inflammatory biomarkers (IB), respiratory (RT) and quadriceps thickness (QT) and diaphragmatic mobility (DM) using muscle ultrasound, body composition (BC) using a bioelectrical impedance scale and inspiratory muscle strength (IMS). RESULTS: after the training, G1 (114.93 ± 21.29) improved IMS (p<0.005) compared with G2 (91.29 ± 23.10) and G3 (85.21 ± 27.02). There was also a significant improve on time of the DM (p<0.001) and RT (p=0.006) for G1 (8.59 ± 3.55 and 11.11 ± 12.66) compared with G2 (1.05 ± 3.09 and 1.10 ± 10.60) and G3 (0.40 ± 2.29 and -1.85 ± 7.45). BDNF, IB, QT and BC were similar between groups. CONCLUSIONS: IMT associated with WBV is effective to improve in increasing IMS, RT and DM in pre-frail older women. However, these interventions do not modify BDNF, IB, QT or BC in this population.
Asunto(s)
Factor Neurotrófico Derivado del Encéfalo , Ejercicios Respiratorios , Músculos Respiratorios , Vibración , Humanos , Femenino , Factor Neurotrófico Derivado del Encéfalo/sangre , Anciano , Vibración/uso terapéutico , Método Doble Ciego , Ejercicios Respiratorios/métodos , Músculos Respiratorios/fisiología , Anciano de 80 o más Años , Fuerza Muscular/fisiología , Persona de Mediana Edad , Biomarcadores/sangre , Inflamación , Composición Corporal/fisiologíaRESUMEN
Inflammatory T lymphocyte cytokines contribute to tissue damage in SLE patients. Vitamin D (Vit D) has a well-established immunomodulatory action, but few studies have addressed the effect of 1,25 dihydroxyvitamin D3 (1,25 (OH)2D3) on peripheral blood mononuclear cells (PBMCs) in SLE patients. The aim of this study was to evaluate the immnunomodulatory effect of 1,25 (OH)2D3 on T lymphocyte-related cytokines. Blood from 27 female SLE patients was collected for PBMC isolation and anti-DNA, complement, and serum 25 (OH)D3 level measurements. PBMCs were stimulated with anti-CD3/anti-CD28 in the presence or absence of dexamethasone or various concentrations of 1,25 (OH)2D3 for 48 h. We assessed IL-17A, IL-22, IL-21, IL-9, IFN-γ, IL-4, IL-10, IL-2, IL-6, and TNF by cytometric bead assay (CBA) and enzyme immune assay (ELISA) on culture supernatant. The mean age of patients was 36.2 (± 10.5 years) and the median Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was 4 (0-6). The addition of 1,25 (OH)2D3 in PBMC culture reduced IL-17 A, IL-22, IL-9, and IFN-γ levels at 100 nM (p ≤ 0.0001). Furthermore, the addition of 1,25 (OH)2D3 at all concentrations increased IL-4 (p ≤ 0.0006), and 0.1 and 1 nM increased IL-10 (p ≤ 0.0004) and 0.1 nM increased IL-2 levels (p ≤ 0.0001). There was no difference regarding IL-21 and TNF levels. The addition of 1,25 (OH)2D3 in PBMC culture presented an inhibitory effect on proinflammatory cytokines and increased immunoregulatory cytokines in SLE patients, suggesting the beneficial effect of this vitamin.
Asunto(s)
Citocinas , Lupus Eritematoso Sistémico , Humanos , Femenino , Adulto , Persona de Mediana Edad , Interleucina-10/farmacología , Leucocitos Mononucleares , Interleucina-2/farmacología , Interleucina-4/farmacología , Interleucina-9 , Linfocitos T , Vitamina D/farmacología , Vitaminas , Lupus Eritematoso Sistémico/tratamiento farmacológicoRESUMEN
BACKGROUND: Although immunostaining of galectins is associated with cartilage damage, the serum levels of these lectins in osteoarthritis (OA) are not fully understood. OBJECTIVE: Therefore, we evaluate the concentrations of galectins-1, 3, 4, and 7 in patients with osteoarthritis and correlate them with clinical parameters. METHODS: This cross-sectional study involved 60 osteoarthritis patients and 43 healthy volunteers, who had serum samples collected for galectins titration by Enzyme-Linked Immunosorbent Assay (ELISA). RESULTS: Our finds showed that the median values of gal-1 and 4 serum levels in patients were statistically higher (13,990 and 969.1 pg/mL, respectively) than in healthy controls (1,798 and 519.5 pg/mL) with p < 0.001. Further, gal-1 expressed higher levels in patients who had joint edema at the time of collection with a median value of 14,970 pg/mL. CONCLUSION: Surprisingly, galectin-4 appears to be involved in the osteoarthritis inflammation process as the well-known galectin-1.
Asunto(s)
Galectina 1 , Osteoartritis , Humanos , Estudios Transversales , GalectinasRESUMEN
INTRODUCTION:: Schistosomiasis is an infectious parasitic disease caused by trematodes of the genus Schistosoma, which threatens at least 258 million people worldwide and its control is dependent on a single drug, praziquantel. The aim of this study was to evaluate the anti-Schistosoma mansoni activity in vitro of novel imidazolidine derivatives. MATERIAL AND METHODS:: We synthesized two novel imidazolidine derivatives: (LPSF/PTS10) (Z)-1-(2-chloro-6-fluorobenzyl)-4-(4-dimethylaminobenzylidene)-5-thioxoimidazolidin-2-one and (LPSF/PTS23) (Z)-1-(2-chloro-6-fluoro-benzyl)-5-thioxo-4-(2,4,6-trimethoxy-benzylidene)-imidazolidin-2-one. The structures of two compounds were determined by spectroscopic methods. During the biological assays, parameters such as motility, oviposition, mortality and analysis by Scanning Electron Microscopy were performed. RESULTS:: LPSF/PTS10 and LPSF/PTS23 were considered to be active in the separation of coupled pairs, mortality and to decrease the motor activity. In addition, LPSF/PTS23 induced ultrastructural alterations in worms, after 24 h of contact, causing extensive erosion over the entire body of the worms. CONCLUSION:: The imidazolidine derivatives containing the trimetoxy and benzylidene halogens showed promising in vitro schistosomicidal activity.
Asunto(s)
Imidazolidinas/farmacología , Células Madre de Sangre Periférica/efectos de los fármacos , Schistosoma mansoni/efectos de los fármacos , Esquistosomicidas/farmacología , Animales , Humanos , Imidazolidinas/síntesis química , Imidazolidinas/toxicidad , Ratones , Microscopía Electrónica de Rastreo , Pruebas de Sensibilidad Parasitaria , Schistosoma mansoni/ultraestructura , Esquistosomicidas/síntesis química , Esquistosomicidas/toxicidad , Factores de TiempoRESUMEN
AIMS: The COVID-19 pandemic suddenly and significantly increased hospitalizations for pneumonia with systemic inflammatory disease. Since its appearance, COVID-19 has affected more than 200 countries, with more than 90 million cases and almost 2 million deaths. So far, there is no quality evidence regarding the specific pharmacological therapy for COVID-19; most treatments usually involve off-label use of existing drugs and have unproven efficacy. The global effort converges on the development of a vaccine; however, the greatest challenge is to achieve collective immunization in the face of increasing vaccination hesitancy. METHODS: This study investigated the impact of vaccine hesitancy movements on the goal of COVID-19 immunization in Brazil. An integrative bibliographic review was performed with an electronic search on PubMed and SciELO that yielded 13.535 articles. Inclusion and exclusion criteria were applied which included 29 interventional and descriptive studies. RESULTS: The results of the 29 studies revealed that the most frequent reasons for hesitation is skepticism about the true interests of the industry and politicians, the lack of trust in research, and inaccurate information on social media. CONCLUSION: The main factors that lead the population not to believe in vaccines were the real interests of industry and politicians, lack of confidence in research, and the amount of false information that circulates massively on social media and because of that it is possible that Brazil will face some challenges in achieving collective immunity due to the anti-vaccine movement.
OBJETIVOS: A pandemia de COVID-19 aumentou repentina e significativamente as hospitalizações por pneumonia com doença inflamatória sistêmica. Desde o seu surgimento, a COVID-19 afetou mais de 200 países, com mais de 90 milhões de casos e quase 2 milhões de mortes. Até o momento, não há evidências de qualidade em relação à terapia farmacológica específica para COVID-19; a maioria dos tratamentos geralmente envolve o uso off-label de medicamentos existentes e sem eficácia comprovada. O esforço global converge para o desenvolvimento de uma vacina; entretanto, o maior desafio é conseguir a imunização coletiva diante do aumento da recusa à vacinação. MÉTODOS: Este estudo investigou o impacto dos movimentos de recusa à vacina no objetivo de imunização com COVID-19 no Brasil. Foi realizada uma revisão bibliográfica integrativa com busca eletrônica no PubMed e SciELO que resultou em 13.535 artigos. Foram aplicados os critérios de inclusão e exclusão que incluíram 29 estudos de intervenção e descritivos. RESULTADOS: Os resultados dos 29 estudos revelaram que os motivos de hesitação mais frequentes são o ceticismo sobre os verdadeiros interesses da indústria e dos políticos, a falta de confiança em pesquisas e informações imprecisas nas redes sociais. CONCLUSÃO: Os principais fatores que levaram a população a não acreditar nas vacinas foram os reais interesses da indústria e dos políticos, a falta de confiança nas pesquisas e a quantidade de informações falsas que circulam massivamente nas redes sociais e por isso é possível que o Brasil enfrente alguns desafios para alcançar a imunidade coletiva devido ao movimento anti-vacinas.
Asunto(s)
Inmunización , Vacunas , Infecciones por Coronavirus , COVID-19RESUMEN
Psoriasis is a common, enigmatic, and recurrent disease. The precise etiology and pathogenesis of psoriasis are still unclear. Psoriasis has been treated as an inflammatory disorder related to an underlying Th1/Th17-dominated immune response. Interleukins are involved in the development of psoriasis lesions through Th-17-associated inflammation. Th1 and Th17 cytokines are found in skin lesions and in the peripheral blood of psoriasis patients. We sought to analyze serum levels of IL-1-ß, IL-8, IL-9, IL-27, IL-29, IL-35, IFN-γ, TNF and TGF-ß in patients with psoriasis and healthy control volunteers. Blood samples were collected from fifty-three patients with psoriasis and thirty-five healthy controls. Serum cytokines concentrations were determined using an enzyme-linked immunosorbent assay. Serum IL-8, IL-9, IL-27, IL-29 and TNF levels were statistically significant in psoriasis patients. Detectable serum IL-9 levels were found in 47 patients of the 53 in the psoriasis group. Interleukins-8, 27, 29 and TNF levels measured in the serum of psoriasis patients were slightly elevated as compared to healthy controls in a weakly significant way. On the other hand, there were highly significant differences in IL-9 levels between the two groups.
Asunto(s)
Citocinas/sangre , Psoriasis/sangre , Psoriasis/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores , Sedimentación Sanguínea , Brasil , Estudios de Casos y Controles , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Psoriasis/tratamiento farmacológico , Sensibilidad y Especificidad , Adulto JovenRESUMEN
The purpose of this paper was to evaluate the levels of IL-9 in patients with SLE and RA compared with controls and the association of IL-9 levels with clinical and laboratory parameters. IL-9 levels were assessed in 117 SLE patients, 67 RA patients, and 24 healthy controls by ELISA. Clinical and laboratory parameters were recorded. The IL-9 serum levels were significantly higher in RA patients (4,77 ± 3,618 pg/mL) and in SLE patients (12,26 ± 25,235 pg/mL) than in healthy individuals (1,22 ± 0,706 pg/mL) (p < 0,001). In SLE patients, there were no statistically significant associations or correlations between the levels of IL-9 and SLEDAI or other clinical and laboratorial parameters, with the exception of disease time, which showed a statistically significant negative correlation with IL-9 levels (r = -0,1948; p = 0,0378). In RA patients, no association or statistically significant correlation was observed with disease duration, DAS28, HAQ, rheumatoid factor positivity, or erosions on radiography. These data demonstrated increased serum levels of IL-9 in SLE and RA patients, but further studies are needed to clarify the precise role of this cytokine and its potential use as therapeutic target.
Asunto(s)
Artritis Reumatoide/metabolismo , Interleucina-9/sangre , Lupus Eritematoso Sistémico/metabolismo , Adulto , Anciano , Artritis Reumatoide/sangre , Biomarcadores/sangre , Femenino , Humanos , Lupus Eritematoso Sistémico/sangre , Masculino , Persona de Mediana Edad , Regulación hacia Arriba , Adulto JovenRESUMEN
ABSTRACT Introduction: Schistosomiasis is an infectious parasitic disease caused by trematodes of the genus Schistosoma, which threatens at least 258 million people worldwide and its control is dependent on a single drug, praziquantel. The aim of this study was to evaluate the anti-Schistosoma mansoni activity in vitro of novel imidazolidine derivatives. Material and methods: We synthesized two novel imidazolidine derivatives: (LPSF/PTS10) (Z)-1-(2-chloro-6-fluorobenzyl)-4-(4-dimethylaminobenzylidene)-5-thioxoimidazolidin-2-one and (LPSF/PTS23) (Z)-1-(2-chloro-6-fluoro-benzyl)-5-thioxo-4-(2,4,6-trimethoxy-benzylidene)-imidazolidin-2-one. The structures of two compounds were determined by spectroscopic methods. During the biological assays, parameters such as motility, oviposition, mortality and analysis by Scanning Electron Microscopy were performed. Results: LPSF/PTS10 and LPSF/PTS23 were considered to be active in the separation of coupled pairs, mortality and to decrease the motor activity. In addition, LPSF/PTS23 induced ultrastructural alterations in worms, after 24 h of contact, causing extensive erosion over the entire body of the worms. Conclusion: The imidazolidine derivatives containing the trimetoxy and benzylidene halogens showed promising in vitro schistosomicidal activity.
Asunto(s)
Humanos , Animales , Ratones , Imidazolidinas/farmacología , Células Madre de Sangre Periférica/efectos de los fármacos , Schistosoma mansoni/efectos de los fármacos , Esquistosomicidas/farmacología , Imidazolidinas/síntesis química , Imidazolidinas/toxicidad , Microscopía Electrónica de Rastreo , Pruebas de Sensibilidad Parasitaria , Schistosoma mansoni/ultraestructura , Esquistosomicidas/síntesis química , Esquistosomicidas/toxicidad , Factores de TiempoRESUMEN
AIMS: Osteoporosis is a common disease that affects mostly women and has been associated with the immune system. The aims of this study were to evaluate the serum levels of inflammatory cytokines in women with postmenopausal osteoporosis and to investigate their relationship with clinical and laboratory parameters. METHODS: This study recruited patients with postmenopausal osteoporosis (osteoporosis group) and non-osteoporotic postmenopausal women (control group) matched for age. All patients and controls had their bone mineral density measured for the diagnosis of osteoporosis and answered a clinical questionnaire. Blood samples were collected for cytokine measurements. Cytokines IFN-γ, IL-1ß, IL-6, IL-8, IL-9, IL-10, IL-17A, IL-22, IL-27, IL-29, IL-35, and TNF-α were measured by an enzyme-linked immunosorbent assay. RESULTS: Twenty-nine out of the 52 (55.8%) postmenopausal osteoporosis patients showed high levels of IL-8, while no patients from the control group (n=21) showed IL-8 values above the detection limit (p<0.0001). Higher levels of IFN-γ and IL-35 were associated with the control group, with p values of 0.0053 and 0.0214, respectively. In the osteoporosis group, IFN-γ was correlated with longer duration of smoking (p=0.003), IFN-γ and IL-6 were correlated with higher age at menarche (p=0.0454 and p=0.0380), IL-22 was correlated with duration of menopause (p=0.0289) and IL-9 with calcium intake (p=0.019). The other cytokines showed no association or correlation with clinical parameters. CONCLUSIONS: IL-8 was elevated in the serum of patients with postmenopausal osteoporosis, perhaps because it may trigger osteoclast activation and bone wear in osteoporosis. Higher levels of IFN-γ, IL-6, IL-9, IL-22, IL-27, and IL-35 were also associated with the osteoporosis group patients and showed significant correlation with clinical parameters in postmenopausal osteoporosis.
OBJETIVOS: A osteoporose é uma doença comum, que afeta principalmente as mulheres e tem sido associada com o sistema imune. Este estudo objetivou avaliar níveis séricos de citocinas inflamatórias em mulheres pós-menopáusicas com osteoporose, assim como investigar as suas relações com parâmetros clínicos e laboratoriais. MÉTODOS: Este estudo recrutou pacientes com osteoporose pós-menopausa e voluntárias sem a doença, pareadas por idade. Todas as pacientes do grupo com osteoporose e as integrantes do grupo controle passaram pelo exame de mensuração de densidade óssea para diagnosticar a doença e todas responderam a um questionário clínico. Amostras de sangue foram coletadas para as dosagens séricas. As citocinas IFN-γ, IL-1ß, IL-6, IL-8, IL-9, IL-10, IL-17A, IL-22, IL-27, IL-29, IL-35 e TNF-α foram dosadas por ensaio imunoenzimático. RESULTADOS: Vinte e nove entre as 52 (55,8%) pacientes com osteoporose pós-menopausa mostraram altos níveis de IL-8, enquanto nenhuma integrante do grupo controle teve valores de IL-8 acima do nível de detecção do kit (p<0,0001). Altos níveis de IFN-γ and IL-35 foram associados ao grupo controle, com valores de p de 0,0053 and 0,0214 respectivamente. No grupo osteoporose, IFN-γ mostrou correlação com o tempo de duração do tabagismo (p=0,003). IFN-γ e IL-6 foram correlacionadas com a idade de ocorrência da menarca (p=0,0454 e p=0,0380). A citocina IL-22 correlacionou-se com a duração da menopausa (p=0,0289), e a IL-9 com a ingestão de mais cálcio na dieta (p=0,019). As outras citocinas dosadas não mostraram associações ou correlações com os parâmetros clínicos. CONCLUSÕES: A IL-8 mostrou-se elevada no soro das pacientes com osteoporose pós-menopausa, talvez por atuar como um gatilho para a ativação dos osteoclastos e desgaste ósseo que ocorre na osteoporose. Níveis mais altos de IFN-γ, IL-6, IL-9, IL-22, IL-27 e IL-35 também estiveram presentes no soro das pacientes do grupo osteoporose e mostraram associações significativas com os parâmetros clínicos na osteoporose pós-menopausa.